- Home
- IMNN vs EDSA Comparison
IMNN vs EDSA Comparison
Compare IMNN & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- EDSA
- Stock Information
- Founded
- IMNN 1982
- EDSA 2015
- Country
- IMNN United States
- EDSA Canada
- Employees
- IMNN N/A
- EDSA N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- EDSA Health Care
- Exchange
- IMNN Nasdaq
- EDSA Nasdaq
- Market Cap
- IMNN 12.1M
- EDSA 13.8M
- IPO Year
- IMNN 1985
- EDSA N/A
- Fundamental
- Price
- IMNN $0.60
- EDSA $2.09
- Analyst Decision
- IMNN Buy
- EDSA Strong Buy
- Analyst Count
- IMNN 2
- EDSA 2
- Target Price
- IMNN $14.00
- EDSA $13.00
- AVG Volume (30 Days)
- IMNN 1.3M
- EDSA 13.3K
- Earning Date
- IMNN 08-13-2025
- EDSA 08-08-2025
- Dividend Yield
- IMNN N/A
- EDSA N/A
- EPS Growth
- IMNN N/A
- EDSA N/A
- EPS
- IMNN N/A
- EDSA N/A
- Revenue
- IMNN N/A
- EDSA N/A
- Revenue This Year
- IMNN N/A
- EDSA N/A
- Revenue Next Year
- IMNN N/A
- EDSA N/A
- P/E Ratio
- IMNN N/A
- EDSA N/A
- Revenue Growth
- IMNN N/A
- EDSA N/A
- 52 Week Low
- IMNN $0.37
- EDSA $1.55
- 52 Week High
- IMNN $3.65
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- IMNN 35.40
- EDSA 55.09
- Support Level
- IMNN $0.70
- EDSA $2.03
- Resistance Level
- IMNN $0.86
- EDSA $2.11
- Average True Range (ATR)
- IMNN 0.07
- EDSA 0.10
- MACD
- IMNN -0.03
- EDSA 0.01
- Stochastic Oscillator
- IMNN 0.05
- EDSA 73.33
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.